Major trial to find best drug for rare autoimmune disease
NCT ID NCT07010302
First seen Feb 18, 2026 · Last updated Jun 02, 2026 · Updated 19 times
Summary
This study compares five FDA-approved drugs (rituximab, ravulizumab, inebilizumab, satralizumab, and eculizumab) to see which one works best to prevent relapses in people with NMOSD, a rare autoimmune condition that can cause vision loss and paralysis. About 160 adults who test positive for a specific antibody will be randomly assigned to one of the treatments. The goal is to help patients and doctors choose the safest and most effective option for long-term disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMOSD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Charité - Universitätsmedizin Berlin
Berlin, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.